Publikationen

Titel Erstautor Letztautor
Journal/Ort Typ Jahr
Entität/Fachrichtung Studie Nummer
Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801)
Vollpublikation 2018
Ösophagus-/Magenkarzinome
www.sciencedirect.com/science/article/pii/S0959804918301138
A randomized phase II study with NIVOlumab or continuation of therapy as an early SWITCH approach in patients with advanced or metastatic renal cell carcinoma (RCC) and disease control after 3 months of treatment with a tyrosine kinase inhibitor- NIVOSWITCH (AIO-NZK-0116)
Abstract 2018
Nierenzellkarzinom
A randomized phase II study with NIVOlumab or continuation of therapy as an early SWITCH approach in patients with advanced or metastatic renal cell carcinoma (RCC) and disease control after 3 months of treatment with a tyrosine kinase inhibitor- NIVOSWITCH (AIO-NZK-0116)
Poster 2018
Nierenzellkarzinom
PREPARE: A phase III study testing the role of PRoactivE coaching on PAtient REported outcome in advanced or metastatic renal cell carcinoma treated with sunitinib (AIO-NZK-0115/ass)
Poster 2018
Nierenzellkarzinom
Vinorelbin plus Everolimus versus Vinorelbin Monotherapy als Zweitlinientherapie des HER2 negativen fortgeschrittenen Mammakarzinoms. Finale Ergebnisse der randomisierten Phase II Studie VicTORia / Vinorelbine plus everolimus versus vinorelbine monotherapy as second-line treatment for HER2-negative advanced breast cancer. Final results from the randomized phase II trial VicTORia
Abstract 2018
Mammakarzinom / gynäkologische Tumoren
Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial
Vollpublikation 2018
Kolon-/Rektum-/Dünndarmtumoren
epub.ub.uni-muenchen.de/59228/index.html
Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial
Vollpublikation 2018
Kolon-/Rektum-/Dünndarmtumoren
www.sciencedirect.com/science/article/pii/S0959804918309092
mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO- KRK0109)
Abstract 2018
Kolon-/Rektum-/Dünndarmtumoren
ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.3509
Serial analysis of mutant KRAS in circulation cell-free DNA (cfDNA) of patients with KRAS mutant metastatic colorectal cancer: A translational study of the KRK0207 trial
Abstract 2018
Kolon-/Rektum-/Dünndarmtumoren
ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e15599
Großangelegtes Registerprojekt CRISP – Dokumentation eines rasanten Therapiewandels
Sonstige 2017
Thorakale Onkologie
www.springermedizin.de/grossangelegtes-registerprojekt-crisp-dokumentation-eines-rasant/12113942